Literature DB >> 11464254

Calcium channel blockers, postural vasoconstriction and dependent oedema in essential hypertension.

R Pedrinelli1, G Dell'Omo, M Mariani.   

Abstract

Treatment with calcium channel blocker (CCB)s, dihydropyridines and others, is frequently complicated by dependent oedema in the absence of sodium retention or cardiac failure, a bothersome side effect of unclear aetiology. The present paper reviews our own and other work dealing with the antagonism exerted by such drugs on postural vasoconstriction, a mechanism triggered by limb venous congestion during orthostasis and controlled through a local sympathetic axo-axonic reflex and increased myogenic tone in response to changes in transmural pressure. By stabilising capillary pressure, postural vasoconstriction counteracts fluid hyperfiltration consequent to gravitational stimuli, and consistent evidence shows attenuation of this response by L-type calcium channel blockers. Interference with the postural reflex control of skin blood flow may therefore contribute to dependent oedema, although cannot entirely explain its development. Attenuation of postural vasoconstriction may amplify the fluid hyperfiltration induced by CCBs through other mechanisms, such as imbalanced intracapillary pressure or enhanced vascular permeability, which are the main factors determining net fluid filtration into the interstitial compartment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11464254     DOI: 10.1038/sj.jhh.1001201

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  20 in total

1.  Cyclosporin enhances the tendency towards oedema and flushing noted on dihydropyridine calcium channel blockers.

Authors:  R O von Vigier; E Fossali; A Edefonti; B Vogt; M G Bianchetti
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

2.  Tolerability and effectiveness of (S)-amlodipine compared with racemic amlodipine in hypertension: a systematic review and meta-analysis.

Authors:  Fang Liu; Meng Qiu; Suo-Di Zhai
Journal:  Curr Ther Res Clin Exp       Date:  2010-02

3.  Optimizing blood pressure control in patients with chronic kidney disease.

Authors:  Biff F Palmer; Andrew Z Fenves
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-07

Review 4.  Progesterone inhibition of neuronal calcium signaling underlies aspects of progesterone-mediated neuroprotection.

Authors:  Jessie I Luoma; Christopher M Stern; Paul G Mermelstein
Journal:  J Steroid Biochem Mol Biol       Date:  2011-11-12       Impact factor: 4.292

5.  Progesterone blocks multiple routes of ion flux.

Authors:  Brooke G Kelley; Paul G Mermelstein
Journal:  Mol Cell Neurosci       Date:  2011-07-19       Impact factor: 4.314

6.  An evaluation of a potential calcium channel blocker-lower-extremity edema-loop diuretic prescribing cascade.

Authors:  Scott Martin Vouri; Joseph S van Tuyl; Margaret A Olsen; Hong Xian; Mario Schootman
Journal:  J Am Pharm Assoc (2003)       Date:  2018-07-20

7.  Human lymphatic vessel contractile activity is inhibited in vitro but not in vivo by the calcium channel blocker nifedipine.

Authors:  Niklas Telinius; Sheyanth Mohanakumar; Jens Majgaard; Sukhan Kim; Hans Pilegaard; Einar Pahle; Jørn Nielsen; Marc de Leval; Christian Aalkjaer; Vibeke Hjortdal; Donna Briggs Boedtkjer
Journal:  J Physiol       Date:  2014-08-28       Impact factor: 5.182

Review 8.  Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension.

Authors:  Keri Wellington; Diana M Faulds
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 9.  Calcium Channel Blockers in Acute Care: The Links and Missing Links Between Hemodynamic Effects and Outcome Evidence.

Authors:  Jin Wang; David L McDonagh; Lingzhong Meng
Journal:  Am J Cardiovasc Drugs       Date:  2021-01       Impact factor: 3.571

10.  The combination of amlodipine/valsartan 5/160 mg produces less peripheral oedema than amlodipine 10 mg in hypertensive patients not adequately controlled with amlodipine 5 mg.

Authors:  J Schrader; A Salvetti; C Calvo; E Akpinar; L Keeling; M Weisskopf; P Brunel
Journal:  Int J Clin Pract       Date:  2009-02       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.